33458-93-4
33458-93-4 structure
- Name: AH 6809
- Chemical Name: 9-oxo-6-propan-2-yloxyxanthene-2-carboxylic acid
- CAS Number: 33458-93-4
- Molecular Formula: C17H14O5
- Molecular Weight: 298.290
- Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
- Create Date: 2018-12-28 06:27:24
- Modify Date: 2024-01-11 08:33:54
-
AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.IC50 Value: ~3 nM (EC50 for calcium mobilization by PGE2) [1]Target: EP/DP receptorin vitro: AH6809also antagonized the aggregatory effect of U-46619 in whole blood (pA2 = 4.45). However, concentrations of AH6809 up to 300 microM were without effect upon either ADP- or platelet activating factor (Paf)-induced aggregation (pA2 less than 3.5) [2]. Preincubation of control cells in 10(-4) M concentrations of AH6809 inhibited PGE2-induced activation of AC by greater than 80% without significant (P greater than .05) inhibition of basal activity by the antagonist [3].in vivo: Exposure to a selective COX-2 inhibitor (SC58125) or an EP1/EP2 antagonist (AH6809), but not an EP4 antagonist (AH23848B), significantly reduced cell proliferation of esophageal explants in 24 hour-organ culture experiments [4]. Oral administration of the EP1 receptor antagonist, AH6809 (10 mg/kg/day, for 4 days), significantly reduced the systolic blood pressure in db/db, but not in control mice [5].
| Name | 9-oxo-6-propan-2-yloxyxanthene-2-carboxylic acid |
|---|---|
| Synonyms |
6-Isopropoxy-9-oxo-9H-xanthene-2-carboxylic acid
Tocris-0671 9H-Xanthene-2-carboxylic acid, 6-(1-methylethoxy)-9-oxo- AH 6809 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid |
| Description | AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors.IC50 Value: ~3 nM (EC50 for calcium mobilization by PGE2) [1]Target: EP/DP receptorin vitro: AH6809also antagonized the aggregatory effect of U-46619 in whole blood (pA2 = 4.45). However, concentrations of AH6809 up to 300 microM were without effect upon either ADP- or platelet activating factor (Paf)-induced aggregation (pA2 less than 3.5) [2]. Preincubation of control cells in 10(-4) M concentrations of AH6809 inhibited PGE2-induced activation of AC by greater than 80% without significant (P greater than .05) inhibition of basal activity by the antagonist [3].in vivo: Exposure to a selective COX-2 inhibitor (SC58125) or an EP1/EP2 antagonist (AH6809), but not an EP4 antagonist (AH23848B), significantly reduced cell proliferation of esophageal explants in 24 hour-organ culture experiments [4]. Oral administration of the EP1 receptor antagonist, AH6809 (10 mg/kg/day, for 4 days), significantly reduced the systolic blood pressure in db/db, but not in control mice [5]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 514.2±50.0 °C at 760 mmHg |
| Molecular Formula | C17H14O5 |
| Molecular Weight | 298.290 |
| Flash Point | 192.9±23.6 °C |
| Exact Mass | 298.084137 |
| PSA | 76.74000 |
| LogP | 3.91 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.618 |
| Storage condition | 2-8℃ |
| Personal Protective Equipment | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |